Synthaverse reports first-half loss. Biomed Lublin stock carries debt

Synthaverse, formerly Biomed Lublin, reported a PLN 6.37 million net loss for the first half of 2026 in a report published on September 30, according to Stockd. The analysis also shows PLN 83.26 million of total debt and PLN 0.35 million of cash, figures that frame the balance-sheet pressure behind Biomed Lublin stock.

Revenue falls despite EBITDA recovery

Revenue reached PLN 26.46 million in the first half of 2026, down 37.00 percent from PLN 42.01 million in the first half of 2025, according to Stockd. The comparison points to a weaker sales base even as operating profitability improved sharply from the prior-year loss.

Operating result improves sharply

EBITDA rose to PLN 5.42 million from a negative PLN 6.54 million in the first half of 2025, an improvement of 182.80 percent, the same analysis reports. EBITDA margin reached 20.46 percent, compared with negative 15.58 percent a year earlier, while the company still posted a net margin of negative 24.06 percent.

Debt remains the central risk

Stockd's September 30 analysis lists total debt of PLN 83.26 million, down 1.60 percent from PLN 84.65 million a year earlier, while cash dropped 79.10 percent to PLN 0.35 million. Current liabilities were PLN 133.90 million against current assets of PLN 116.73 million, leaving the current ratio at 0.87 times. The figures make liquidity and refinancing central to the investment case rather than secondary balance-sheet details.

Warsaw quote stays below yearly high

On October 1, 2026 at 11:28 a.m. CEST, Synthaverse traded at PLN 2.83 on the Warsaw Stock Exchange, down 0.53 percent from PLN 2.85. The 52-week range was PLN 2.60 to PLN 4.40, while market capitalization stood at PLN 215.5 million on the same date.